<div id="readability-page-1"><p>AC Immune (NASDAQ:ACIU - Get Free Report)'s stock price crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $3.00 and traded as low as $2.59. AC Immune shares last traded at $2.75, with a volume of 127,564 shares changing hands.</p><h2>Analyst Ratings Changes</h2><p>ACIU has been the topic of a number of analyst reports. BTIG Research  reiterated a &#34;buy&#34; rating and set a $8.00 price objective on shares of AC Immune in a research note on Monday, March 16th. Jefferies Financial Group  reaffirmed a &#34;buy&#34; rating and set a $7.00 price target on shares of AC Immune in a report on Friday, March 13th. Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of AC Immune in a research note on Wednesday, January 21st. Finally, Wall Street Zen upgraded shares of AC Immune from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, February 28th. Three analysts have rated the stock with a Buy rating, one  has assigned  a Hold rating and one  has assigned  a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of &#34;Hold&#34; and an average target price of $9.00.</p><p><b>View Our Latest Stock Analysis on AC Immune</b></p><h2>AC Immune Trading Up 7.4%</h2><p>The business has a 50 day simple moving average of $3.00 and a two-hundred day simple moving average of $3.09. The stock has a market cap of $279.87 million, a price-to-earnings ratio of -3.27 and a beta of 1.64. </p><p>AC Immune (NASDAQ:ACIU - Get Free Report) last announced its earnings results on Friday, March 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.01. The company had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.14 million. AC Immune had a negative return on equity of 103.15% and a negative net margin of 1,977.71%. Research analysts anticipate that  AC Immune will post -0.62 EPS for the current fiscal year. </p><h2>Institutional Inflows and Outflows</h2><p>A number of large investors have recently added to or reduced their stakes in the stock. EFG International AG bought a new stake in shares of  AC Immune in the 4th quarter worth about $41,000.  Marshall Wace LLP acquired a new stake in shares of  AC Immune during the fourth quarter worth $586,000.  Dimensional Fund Advisors LP raised its holdings in shares of  AC Immune by 20.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 213,464 shares of the company's stock worth $670,000 after purchasing an additional 36,353 shares during the period.  Goldman Sachs Group Inc. lifted its position in shares of  AC Immune by 46.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company's stock worth $58,000 after buying an additional 5,920 shares during the last quarter.  Finally, Susquehanna International Group LLP bought a new position in shares of  AC Immune in the 3rd quarter worth about $63,000. 51.36% of the stock is currently owned by institutional investors. </p><h2>AC Immune Company Profile</h2> (Get Free Report)<p>AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates. </p><p>Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.</p><h2>See Also</h2><ul><li>Five stocks we like better than AC Immune</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in AC Immune Right Now?</h2><p>Before you consider AC Immune, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AC Immune wasn't on the list.</p><p>While AC Immune currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SBIO

<p>AC Immune's stock (NASDAQ:ACIU) fell below its 50-day moving average of $3.00, trading as low as $2.59 before closing at $2.75. Analysts have mixed ratings, with three recommending a buy, one a hold, and one a sell, leading to a consensus hold rating and an average target price of $9.00. The company reported a quarterly EPS of ($0.18), slightly beating estimates, but revenue fell short at $0.44 million. Institutional investors hold 51.36% of the stock, indicating significant interest despite recent price declines.</p>

Market Beat

iShares Biotechnology ETF

ALPS Medical Breakthrough

VG Health

Direxion S&P Biotech Bull 3X

Health Care Select Sector SPDR

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

iShares Global Healthcare

VanEck Biotech ETF

iShares US Pharma

Ark Genomic Revolution ETF

AC Immune

SPDR S&P Biotech

AC Immune (NASDAQ:ACIU) Stock Price Passes Below Fifty Day Moving Average   - Here's Why